The Medicines Company announced that detailed results from the ORION-9 and ORION-10 pivotal Phase 3 clinical studies of inclisiran will be presented during late-breaking science sessions at the American Heart Association (AHA) Scientific Sessions 2019, November 16-18, in Philadelphia. The Company will also be hosting and sponsoring educational sessions intended to help advance the cardiology community’s efforts to overcome the global healthcare challenge and burden – cardiovascular disease – and address cumulative exposure to low-density lipoprotein cholesterol (LDL-C), a leading risk factor for the development of atherosclerotic cardiovascular disease (ASCVD). Inclisiran is The Medicines Company’s investigational twice-yearly therapy to reduce LDL-C and the first and only cholesterol-lowering therapy in the small-interfering RNA (siRNA) class. ORION is a comprehensive research program studying the efficacy and safety of inclisiran in patients with ASCVD and familial hypercholesterolemia and includes three pivotal Phase 3 LDL-C lowering studies, ORION-9, ORION-10 and ORION-11.